Cancer and Metastasis Reviews

Cancer and Metastasis Reviews is a quarterly peer-reviewed journal published by Springer, founded in 1982 and devoted to reviews on the biology and treatment of malignant disease, with a 2025 Journal Impact Factor of 12.7《癌症与转移评论》（Cancer and Metastasis Reviews）是由（Springer）出版的季度同行评审期刊，1982 年创刊，专注恶性肿瘤生物学与治疗的综述，2025 年影响因子为 12.7。

Scope

• It publishes outstanding reviews on recent developments in the biology and treatment of malignant disease该刊发表关于恶性肿瘤生物学与治疗最新进展的优质综述。
• It focuses on the molecular and cellular biology of cancer metastasis and tumor progression该刊聚焦癌症转移与肿瘤进展的分子与细胞生物学。^[1]
• It presents expert contributions on a single theme or topic in each issue其每期围绕单一主题或话题呈献专家稿件。
• Its topics include oncogenes and tumor suppressors, cell death regulation, the cell cycle, DNA repair, inflammation, the microbiome, cell metabolism, epigenetics and the tumor microenvironment其主题包括癌基因与抑癌基因、细胞死亡调控、细胞周期、DNA 修复、炎症、微生物组、细胞代谢、表观遗传学与肿瘤微环境。^[2]
• It also covers molecularly targeted therapies, immunotherapies, predictive biomarkers, early detection technologies and cancer disparities该刊还涵盖分子靶向疗法、免疫疗法、预测性生物标志物、早期检测技术与癌症差异。
• Its goal is to highlight recent significant advances in basic, translational and clinical research其目标是突出基础、转化与临床研究中的最新重要进展。

History

• The journal was founded in 1982 by Isaiah J. Fidler, Garth L. Nicolson and George Poste该刊由 Isaiah J. Fidler、Garth L. Nicolson 与 George Poste 于 1982 年创办。
• Its founding editor Isaiah J. Fidler was a pioneer in cancer metastasis research who died in 2020创刊编辑 Isaiah J. Fidler 是癌症转移研究的先驱，于 2020 年去世。
• Garth L. Nicolson is now recognized as Emeritus and George Poste is based at Arizona State UniversityGarth L. Nicolson 现为荣休编辑，George Poste 任职于（Arizona State University）。
• It is published quarterly by Springer and is now an online-only journal whose print ISSN has ceased该刊由（Springer）按季出版，现为仅在线发行的期刊，纸质 ISSN 已停用。
• The 2024 Journal Impact Factor is 8.7 with a 5-year Journal Impact Factor of 10.1, rising to 12.7 in 2025该刊 2024 年影响因子为 8.7，五年影响因子为 10.1，2025 年升至 12.7。
• Its median time from submission to first decision is 8 days, and its articles drew 962.8 thousand downloads in 2025从投稿到首次决定的中位时间为 8 天，其文章 2025 年下载量达 96.28 万次。

Editors

• The Editor-in-Chief is Erica A. Golemis of Fox Chase Cancer Center and the Lewis Katz School of Medicine at Temple University主编为（Fox Chase Cancer Center）与（Lewis Katz School of Medicine at Temple University）的 Erica A. Golemis。
• The Associate Editors are Guangwen Ren of The Jackson Laboratory and Qin Yan of Yale School of Medicine副编辑为（The Jackson Laboratory）的 Guangwen Ren 与（Yale School of Medicine）的 Qin Yan。
• Editorial Advisory Board members include Richard Bayliss of the University of Leeds and Barbara Burtness of Yale Cancer Center编委会顾问成员包括（University of Leeds）的 Richard Bayliss 与（Yale Cancer Center）的 Barbara Burtness。
• Other advisory board members include David Cheresh, Petros Christopoulos, Hongbin Ji and Haitao Li其他顾问成员包括 David Cheresh、Petros Christopoulos、Hongbin Ji 与 Haitao Li。
• Board members also include Bora Lim, Vivek Mittal, Danny Welch, Gelareh Zadeh and Qing Zhang编委还包括 Bora Lim、Vivek Mittal、Danny Welch、Gelareh Zadeh 与 Qing Zhang。
• It uses a hybrid publishing model that offers both subscription and open access publication该刊采用混合出版模式，同时提供订阅与开放获取出版。